Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
about
PCSK9 inhibition: the way forward in the treatment of dyslipidemiaProfile of evolocumab and its potential in the treatment of hyperlipidemiaDevelopment of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersPCSK9 inhibitors in the prevention of cardiovascular diseaseUS physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry.Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemiaAlirocumab (Praluent): First in the New Class of PCSK9 InhibitorsThe PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsEfficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction.PCSK9 inhibition: current concepts and lessons from human genetics.Targeting PCSK9 for therapeutic gainsPCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.An evaluation of alirocumab for the treatment of hypercholesterolemia.Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications.Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.Alirocumab: A Review in Hypercholesterolemia.Monoclonal Antibodies for Lipid Management.Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.PCSK9 Inhibitors: Treating the Right Patients in Daily Practice.Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials.Annual Congress of the European Society of Cardiology: Aug 30-Sept 3 2014; Barcelona, Spain.PCSK9 inhibitor valuation: A science-based review of the two recent models.
P2860
Q26784482-A797029C-45BC-436C-B2D9-0255FC27434FQ27004235-F4ABE380-921A-4868-98F7-D014CAA0567BQ28070296-5E2C4F9D-13F7-4881-BC6A-365776A48C34Q28071452-D0F12BFE-7754-403C-8E0F-426B978A1910Q31133478-2AEC1B24-7E8F-43F6-B2A7-BA81FB39D816Q36130225-24FBD979-9581-4009-A6EB-786B609E760BQ36278291-F1A904D1-42D3-4BE0-B267-CCD1C19D8B95Q36425306-BC4FAD2D-CB65-4366-95B9-E8A4B0F4EABFQ36480595-5F97789C-B6EE-47A4-85BB-7FFE59786C26Q37011769-69C327C9-16D0-425D-BD19-08B86568D2D6Q37364393-926FB4D0-F168-4EC4-8685-27130CF2842AQ37688760-70C5B56C-352D-4422-BC15-E0BEC176C105Q38253151-B45A1B77-CEEF-4B53-B6EF-8CA222BE4C22Q38338236-E35CC978-D9BA-403B-8EAD-048DC479E703Q38364882-789A38DD-7984-463F-A5EE-FC511FA5AAAFQ38525880-C77D244A-AD3C-4A80-9F33-B42A74527750Q38631018-FB5BDF37-F36C-4A5E-9DC0-8F1B1E7A38AEQ38632198-8463BCF1-4249-4E98-9267-85D4BB94E2DBQ38702989-C3EB57FB-ECAB-4B4B-81DB-7E28FEDF8579Q38727796-6C8E6AEF-8465-43EC-B1AA-97ABC6751592Q38748829-E237E37E-D537-464C-8D07-875A516CB0A1Q38758372-34C90ED9-0228-46B8-8CBE-BCB80BCA80ABQ38843479-47D6E2EC-D348-4634-9BC8-416758465B2FQ38938935-C4062DFF-7CD3-42AA-B767-099172F0512CQ39034676-635018DC-7BCF-410D-91DD-FB1684B621D0Q39393317-1BDFE009-E96C-4D7A-BC70-1AAD30A0CA9DQ50109199-1401DD21-C9D6-4A51-9B79-B30667C39165Q51272402-D3280084-21B9-4F75-A839-81A840A9DFDBQ52364662-64C5199F-0CB9-4835-B377-0B072CC3D6E0
P2860
Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Efficacy and safety of alirocu ...... ale of the ODYSSEY FH studies.
@ast
Efficacy and safety of alirocu ...... ale of the ODYSSEY FH studies.
@en
type
label
Efficacy and safety of alirocu ...... ale of the ODYSSEY FH studies.
@ast
Efficacy and safety of alirocu ...... ale of the ODYSSEY FH studies.
@en
prefLabel
Efficacy and safety of alirocu ...... ale of the ODYSSEY FH studies.
@ast
Efficacy and safety of alirocu ...... ale of the ODYSSEY FH studies.
@en
P2093
P2860
P1476
Efficacy and safety of alirocu ...... ale of the ODYSSEY FH studies.
@en
P2093
Christelle Lorenzato
Daniel A Gipe
Gisle Langslet
Jennifer G Robinson
John J P Kastelein
Marie T Baccara-Dinet
Michel Farnier
P2860
P304
P356
10.1007/S10557-014-6523-Z
P577
2014-06-01T00:00:00Z